More tools:Markets·Screener·Research·Chat

Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) Financial Statements

Rani Therapeutics Holdings, Inc. Class A Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG011R6PZZ0
XNAS · usd
0.87▲ 0.01 (0.83%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close0.87
Day's Range0.86 – 0.90
52-Week Range0.45 – 3.87
Volume529.7K
Avg Volume636.4K
Share Statistics
Shares Outstanding
Employees69
ExchangeXNAS
Listed2021-07-30
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI)
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's Market Cap?
Rani Therapeutics Holdings, Inc. Class A Common Stock's Market Cap is $121.6M, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's Enterprise Value?
Rani Therapeutics Holdings, Inc. Class A Common Stock's Enterprise Value is $116.8M, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's Price / Sales?
Rani Therapeutics Holdings, Inc. Class A Common Stock's Price / Sales is 24.9×, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's EV / Revenue?
Rani Therapeutics Holdings, Inc. Class A Common Stock's EV / Revenue is 23.9×, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's EV / EBITDA?
Rani Therapeutics Holdings, Inc. Class A Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's Revenue (TTM)?
Rani Therapeutics Holdings, Inc. Class A Common Stock's Revenue (TTM) is $4.9M, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's Net Income (TTM)?
Rani Therapeutics Holdings, Inc. Class A Common Stock's Net Income (TTM) is -$30.1M, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's EBITDA?
Rani Therapeutics Holdings, Inc. Class A Common Stock's EBITDA is -$32.2M, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's Diluted EPS (TTM)?
Rani Therapeutics Holdings, Inc. Class A Common Stock's Diluted EPS (TTM) is -0.22, based on as-reported figures from SEC (XBRL) filings.
What is Rani Therapeutics Holdings, Inc. Class A Common Stock's EBITDA Margin?
Rani Therapeutics Holdings, Inc. Class A Common Stock's EBITDA Margin is -661.0%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Contract revenue
YoY growth—+893.0%+42.1%—
Operating expenses
Research and development
General and administrative
Total operating expenses
% of revenue616.9%588.2%684.2%—
Loss from operations
% of revenue-516.9%-488.2%-584.2%—
Other income (expense), net
Interest income and other, net
Interest expense and other, net
Net loss
% of revenue-493.0%-469.3%-621.1%—
Net loss attributable to non-controlling interest
Net loss attributable to Rani Therapeutics Holdings, Inc.
% of revenue-432.7%-411.8%-705.3%—
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-Basic—
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted—